Launch week offerEnds in00h00m00s

Anke Salmen

Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2025

Background: Reporting of sex-specific analyses in multiple sclerosis (MS) is sparse. Disability accrual results from relapses (relapse-associated worsening) and independent thereof (progression independent of relapses). Objectives: A population of MS patients during relapse treated per standard of care was analyzed for sex differences and short-term relapse outcome (3–6 months) as measured by Expanded Disability Status Scale (EDSS) change. Design: Single-center retrospective study. Methods: We analyzed 134 MS relapses between March 2016 and August 2020. All events required relapse treatment (steroids and/or plasma exchange). Demographic, disease, and paraclinical characteristics [cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI)] were displayed separated by sex. Multivariable linear regression was run to identify factors associated with short-term EDSS change. Results: Mean age at relapse was 38.4 years (95% confidence interval: 36.3–40.4) with a proportion of 71.6% women in our cohort. Smoking was more than twice as prevalent in men (65.8%) than women (32.3%). In- and after-relapse EDSSs were higher in men [men: 3.3 (2.8–3.9), women: 2.7 (2.4–3.0); men: 3.0 (1.3–3.6); women: 1.8 (1.5–2.1)] despite similar relapse intervention. Paraclinical parameters revealed no sex differences. Our primary model identified female sex, younger age, and higher EDSS at relapse to be associated with EDSS improvement. A higher immunoglobulin G (IgG) quotient (CSF/serum) was associated with poorer short-term outcome [mean days between first relapse treatment and last EDSS assessment 130.2 (79.3–181.0)]. Conclusion: Sex and gender differences are important in outcome analyses of MS relapses. Effective treatment regimens need to respect putative markers for a worse outcome to modify long-term prognosis such as clinical and demographic variables, complemented by intrathecal IgG synthesis. Prospective trials should be designed to address these differences and confirm our results.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Caroline Pot

Associate Professor

Lausanne University Hospital

SWITZERLAND
View details

Özgür Yaldizli

-

SWITZERLAND
View details

Ramona-Alexandra Todea

University Hospital of Zurich

SWITZERLAND
View details

Stefanie Marti

University Hospital of Bern

SWITZERLAND
View details

Mario Ocampo-Pineda

University of Basel

SWITZERLAND
View details

Helly Hammer

University Hospital of Bern

SWITZERLAND
View details

Robert Hoepner

Head of Neuroimmunological Outpatient Department and Neuroimmunological Study Cetner

University Hospital of Bern

SWITZERLAND
View details

Philippe C. Cattin

Department Head

University of Basel

SWITZERLAND
View details

Andrew Chan

Chief Physician, Deputy Head of Department, Head of Medical Division Neuro

University Hospital of Bern

SWITZERLAND
View details

Martina Absinta

Humanitas University

ITALY
View details

Ludwig Kappos

Professor

University of Basel

SWITZERLAND
View details

Alessandro Cagol

-

SWITZERLAND
View details